var data={"title":"ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">ACE inhibitors, angiotensin receptor blockers, and atrial fibrillation</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/contributors\" class=\"contributor contributor_credentials\">E Kevin Heist, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/contributors\" class=\"contributor contributor_credentials\">Samuel L&eacute;vy, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/contributors\" class=\"contributor contributor_credentials\">Hugh Calkins, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/contributors\" class=\"contributor contributor_credentials\">Gordon M Saperia, MD, FACC</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 06, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Initial studies suggested that angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and (possibly) aldosterone antagonists might either prevent new onset and recurrent atrial fibrillation (AF) or reduce the rate of major adverse cardiovascular outcomes in these patients. However, the available data do not support the use of these drugs solely for these purposes.</p><p>In this topic ACE inhibitors and ARBs collectively will be referred to as &lsquo;angiotensin inhibition.&rsquo;</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">POSSIBLE MECHANISMS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Mechanisms proposed to explain the benefit of angiotensin blockade found in the early studies included the direct effects of angiotensin blockade on the structural and electrical properties of the atria, as well as the indirect influence of improved control of heart failure and hypertension (in patients with these conditions), both of which are known risk factors for atrial fibrillation (AF) [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"topic.htm?path=the-electrocardiogram-in-atrial-fibrillation\" class=\"medical medical_review\">&quot;The electrocardiogram in atrial fibrillation&quot;</a> and <a href=\"topic.htm?path=actions-of-angiotensin-ii-on-the-heart\" class=\"medical medical_review\">&quot;Actions of angiotensin II on the heart&quot;</a> and <a href=\"topic.htm?path=epidemiology-of-and-risk-factors-for-atrial-fibrillation\" class=\"medical medical_review\">&quot;Epidemiology of and risk factors for atrial fibrillation&quot;</a>.)</p><p>The following observations supported the proposed mechanisms:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reduction in atrial stretch &mdash; Atrial stretch, due to increased left atrial (LA) pressure, is associated with changes in the refractory period and conduction properties of atrial myocardium. These abnormalities provide both potential triggers and the substrate for the initiation and perpetuation of AF. The hemodynamic effects of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) result in improved ventricular function and also reductions in LA pressure and wall stress [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/2\" class=\"abstract_t\">2</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prevention of atrial fibrosis &mdash; Fibrosis in the atrial myocardium may be an important component of the substrate necessary for AF. Atrial fibrosis is stimulated by elevated levels of angiotensin-II [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/3\" class=\"abstract_t\">3</a>] and reduced by treatment with ACE inhibitors [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/4,5\" class=\"abstract_t\">4,5</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prevention of electrical remodeling and direct antiarrhythmic effects &mdash; Direct effects of angiotensin blockade on ion channels and electrophysiologic properties have been suggested [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/6\" class=\"abstract_t\">6</a>], but data from both animal and human studies have been conflicting and inconclusive. Canine work has suggested direct inhibition of triggering of atrial arrhythmias by ACE inhibitors and ARBs [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/7\" class=\"abstract_t\">7</a>]. </p><p/><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">PREVENTION OF NEW ONSET AF</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Post-hoc analyses of randomized trials and observations from nonrandomized studies have suggested that angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) reduce the incidence of new atrial fibrillation (AF) in a variety of settings including the treatment of left ventricular dysfunction or hypertension, and after coronary artery bypass graft surgery (CABG). </p><p>The following findings were noted in a 2010 meta-analysis of data from 26 randomized trials [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/8\" class=\"abstract_t\">8</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>ACE inhibitors and ARBs significantly reduced the risk of the development of AF (Odds Ratio [OR] 0.65, 95% CI 0.55-0.76); the benefit was equivalent with the two classes of drugs.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The benefit of ACE inhibitors and ARBs appeared large in patients with systolic heart failure (OR 0.50), but the result was not statistically significant (95% CI 0.19-1.16).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The effect of ACE inhibitors and ARBs was greater in preventing recurrent AF (OR 0.45, 95% CI 0.31-0.65) compared to new-onset AF (OR 0.80, 95% CI 0.70-0.92)</p><p/><p>However, the strength of the conclusions from the meta-analysis is weakened due the inclusion of post hoc analyses of randomized trials performed for reasons other than prevention of AF (eg, heart failure, post-myocardial infarction [MI], or hypertension), heterogeneity, and the likely presence of publication or ascertainment bias.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Left ventricular dysfunction or heart failure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the TRACE trial of patients with left ventricular dysfunction and sinus rhythm after an acute myocardial infarction, <a href=\"topic.htm?path=trandolapril-drug-information\" class=\"drug drug_general\">trandolapril</a> therapy was associated with a significantly reduced incidence of subsequent AF at two- to four-year follow-up (2.8 versus 5.3 percent with placebo) [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/9\" class=\"abstract_t\">9</a>].</p><p>Similar findings were noted in retrospective analyses from the randomized trials SOLVD and Val-HeFT, which enrolled patients with chronic left ventricular dysfunction, almost all of whom had ischemic heart disease [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/10,11\" class=\"abstract_t\">10,11</a>]. In the SOLVD trial, <a href=\"topic.htm?path=enalapril-drug-information\" class=\"drug drug_general\">enalapril</a> significantly reduced the incidence of subsequent AF at a mean follow-up of 2.9 years (5.4 versus 24 percent with placebo, hazard ratio 0.22). (See <a href=\"topic.htm?path=use-of-angiotensin-converting-enzyme-inhibitors-in-heart-failure-with-reduced-ejection-fraction\" class=\"medical medical_review\">&quot;Use of angiotensin converting enzyme inhibitors in heart failure with reduced ejection fraction&quot;</a> and <a href=\"topic.htm?path=angiotensin-converting-enzyme-inhibitors-and-receptor-blockers-in-acute-myocardial-infarction-clinical-trials\" class=\"medical medical_review\">&quot;Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials&quot;</a>.)</p><p>A smaller reduction in the incidence of new AF with the ARB <a href=\"topic.htm?path=candesartan-drug-information\" class=\"drug drug_general\">candesartan</a> was noted in the CHARM trials [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/12\" class=\"abstract_t\">12</a>]. Among 7601 patients enrolled in the three trials, 6379 patients did not have AF at baseline. At a median follow-up of 38 months, candesartan produced a reduction in the incidence of new AF (5.6 versus 6.7 percent, adjusted P value 0.039).</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Hypertension</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Some [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/13-17\" class=\"abstract_t\">13-17</a>], but not all [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/18-20\" class=\"abstract_t\">18-20</a>], studies comparing ACE inhibitors or ARBs to other classes of drugs in patients with hypertension have shown a lowering of the risk of development AF. A 2010 meta-analysis of trials with substantial heterogeneity found no significant reduction in the risk for AF [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/21\" class=\"abstract_t\">21</a>]. </p><p>Societal guidelines and our recommendations for the use of angiotensin inhibition to prevent AF are found below. (See <a href=\"#H986438\" class=\"local\">'Recommendations of others'</a> below and <a href=\"#H11\" class=\"local\">'Summary and recommendations'</a> below.) </p><p>The role of angiotensin blockade in the treatment of hypertension is discussed separately. (See <a href=\"topic.htm?path=choice-of-drug-therapy-in-primary-essential-hypertension#H28\" class=\"medical medical_review\">&quot;Choice of drug therapy in primary (essential) hypertension&quot;, section on 'Summary and recommendations'</a>.)</p><p class=\"headingAnchor\" id=\"H621977831\"><span class=\"h2\">Patients with other risk factors for AF</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The issue of whether these therapies might prevent the development of AF in patients with risk factors other than left ventricular dysfunction, heart failure, or hypertension, such as diabetes or coronary artery disease, has not been well studied. (See <a href=\"topic.htm?path=epidemiology-of-and-risk-factors-for-atrial-fibrillation\" class=\"medical medical_review\">&quot;Epidemiology of and risk factors for atrial fibrillation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Coronary artery bypass graft</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The possible role of these therapies for the prevention of AF in patients undergoing cardiac surgery is discussed elsewhere. (See <a href=\"topic.htm?path=atrial-fibrillation-and-flutter-after-cardiac-surgery#H97330379\" class=\"medical medical_review\">&quot;Atrial fibrillation and flutter after cardiac surgery&quot;, section on 'Ineffective or possibly effective therapies'</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">PREVENTION OF RECURRENT AF</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Multiple small studies have demonstrated reduction in recurrent atrial fibrillation (AF) with use of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), but these findings have not been confirmed in larger, better powered studies.</p><p>In small trials that enrolled fewer than 200 patients, ACE inhibitors or ARBs in combination with <a href=\"topic.htm?path=amiodarone-drug-information\" class=\"drug drug_general\">amiodarone</a> reduced the rate of recurrent AF compared with amiodarone alone [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/22-26\" class=\"abstract_t\">22-26</a>]. A small study of <a href=\"topic.htm?path=ramipril-drug-information\" class=\"drug drug_general\">ramipril</a> versus placebo in hypertensive patients demonstrated reduced AF recurrence with ramipril [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/26\" class=\"abstract_t\">26</a>] and a small randomized study comparing <a href=\"topic.htm?path=telmisartan-drug-information\" class=\"drug drug_general\">telmisartan</a> to <a href=\"topic.htm?path=carvedilol-drug-information\" class=\"drug drug_general\">carvedilol</a> in hypertensive patients with prior AF demonstrated less recurrence of AF in patients treated with telmisartan, despite similar blood pressure reduction between the two agents [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/27\" class=\"abstract_t\">27</a>]. However, these results from smaller studies were not confirmed in the GISSI-AF trial, which randomly assigned 1442 patients with a history of symptomatic AF and in sinus rhythm to receive either <a href=\"topic.htm?path=valsartan-drug-information\" class=\"drug drug_general\">valsartan</a> or placebo [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/28\" class=\"abstract_t\">28</a>]. All patients had underlying cardiovascular disease, diabetes, or left atrial enlargement.</p><p>GISSI-AF found that <a href=\"topic.htm?path=valsartan-drug-information\" class=\"drug drug_general\">valsartan</a> did NOT prevent recurrent AF. At one-year follow-up, there was no significant difference between valsartan or placebo in the proportion of patients who had more than one episode of AF (51 versus 52 percent, adjusted hazard ratio 0.97, 95% CI 0.83-1.14) or in the median time from randomization to the first recurrence of AF (295 versus 291 days). Although 57 percent of patients were taking an ACE inhibitor and 70 percent were taking antiarrhythmic drugs at baseline that were continued throughout the trial and might have confounded the results, the outcomes in subgroup analysis were similar in the patients who were or were not being treated with such agents.</p><p>Another possible contributor to the lack of benefit in GISSI-AF was a low prevalence of heart <span class=\"nowrap\">failure/left</span> ventricular dysfunction (8 percent), since the meta-analysis cited above found that the benefit was greatest in patients with these conditions [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/29\" class=\"abstract_t\">29</a>].</p><p>Prevention of recurrent AF with <a href=\"topic.htm?path=irbesartan-drug-information\" class=\"drug drug_general\">irbesartan</a> was also analyzed in the ACTIVE I study, which randomized 9016 patients with a history of AF, stroke risk factors and a systolic blood pressure of at least 110 mm Hg to either irbesartan 300 mg once daily or placebo. Patients who received irbesartan in ACTIVE I were not significantly more likely to be in sinus rhythm at subsequent follow-up, regardless of whether they were initially in AF at baseline or in sinus rhythm at baseline (RR 0.97, p = 0.61). Similarly, the ANTIPAF study, a randomized study of placebo versus <a href=\"topic.htm?path=olmesartan-drug-information\" class=\"drug drug_general\">olmesartan</a> in patients with documented paroxysmal AF, demonstrated no benefit in regard to recurrent AF episodes in patients randomized to olmesartan [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/30\" class=\"abstract_t\">30</a>].</p><p class=\"headingAnchor\" id=\"H615512240\"><span class=\"h2\">Aldosterone inhibition and AF</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are data from animal and human studies to suggest that <a href=\"topic.htm?path=spironolactone-drug-information\" class=\"drug drug_general\">spironolactone</a>, an aldosterone antagonist, may reduce recurrent AF [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/31,32\" class=\"abstract_t\">31,32</a>]. A newer aldosterone antagonist, <a href=\"topic.htm?path=eplerenone-drug-information\" class=\"drug drug_general\">eplerenone</a>, was shown in the randomized EMPHASIS-HF study to reduce new onset AF in patients with systolic heart failure and mild heart failure symptoms [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/33\" class=\"abstract_t\">33</a>]. Eplerenone was also shown in a small study to decrease AF recurrence after catheter ablation for long-standing persistent AF [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/34\" class=\"abstract_t\">34</a>]. Although there appears to be potential benefit to the use of aldosterone inhibitors in heart failure patients, we do not recommend aldosterone inhibitors specifically for prevention of new or recurrent AF. (See <a href=\"topic.htm?path=use-of-mineralocorticoid-receptor-antagonists-in-heart-failure-with-reduced-ejection-fraction\" class=\"medical medical_review\">&quot;Use of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction&quot;</a>.) &#160;</p><p class=\"headingAnchor\" id=\"H615512079\"><span class=\"h2\">Catheter ablation of AF</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The data are mixed as to whether ACE <span class=\"nowrap\">inhibitors/ARBs</span> reduce AF after radiofrequency catheter ablation procedures: A significant benefit was seen in some [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/35\" class=\"abstract_t\">35</a>], but not other [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/36,37\" class=\"abstract_t\">36,37</a>] studies. (See <a href=\"topic.htm?path=catheter-ablation-to-prevent-recurrent-atrial-fibrillation-clinical-applications\" class=\"medical medical_review\">&quot;Catheter ablation to prevent recurrent atrial fibrillation: Clinical applications&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H110572908\"><span class=\"h1\">PREVENTION OF CARDIOVASCULAR EVENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As discussed in the sections on prevention above, the benefit of either angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blockers (ARB) therapy for the prevention of new or recurrent atrial fibrillation (AF) is uncertain. The issue of whether ARB therapy can reduce the rate of major adverse cardiovascular events in patients with AF was addressed in the ACTIVE I trial, which enrolled individuals with either permanent AF or at least two episodes of intermittent AF (in the previous six months) from the ACTIVE A and ACTIVE W trials [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/38\" class=\"abstract_t\">38</a>]. (See <a href=\"#H9\" class=\"local\">'Prevention of recurrent AF'</a> above and <a href=\"topic.htm?path=atrial-fibrillation-anticoagulant-therapy-to-prevent-embolization#H124800782\" class=\"medical medical_review\">&quot;Atrial fibrillation: Anticoagulant therapy to prevent embolization&quot;, section on 'Potential alternatives to anticoagulant monotherapy'</a>.)</p><p>Mean reductions in systolic and diastolic blood pressures were 2.9 and 1.9 mmHg greater in the <a href=\"topic.htm?path=irbesartan-drug-information\" class=\"drug drug_general\">irbesartan</a> group. At a mean follow-up of 4.1 years, there was no significant difference in the rates of the first combined coprimary outcome of stroke, myocardial infarction, or death from vascular causes for the irbesartan compared with placebo groups (5.4 percent per 100 person-years in both groups), and there was no significant difference in the rates of the second combined coprimary outcome, which included the components of the first coprimary outcome plus the rate of hospitalization for heart failure (7.3 and 7.7 percent per 100 person-years in the two groups, respectively).</p><p>The potential benefit from the use of ACE inhibitor and ARB therapy in patients with cardiovascular disease is discussed elsewhere. (See <a href=\"topic.htm?path=what-is-goal-blood-pressure-in-the-treatment-of-hypertension#H126130858\" class=\"medical medical_review\">&quot;What is goal blood pressure in the treatment of hypertension?&quot;, section on 'Our approach to goal blood pressure'</a>.) </p><p class=\"headingAnchor\" id=\"H986438\"><span class=\"h1\">RECOMMENDATIONS OF OTHERS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Our experts do not believe the evidence is strong enough to support the recommendations made by the European Society of Cardiology (ESC) for either the primary prevention of new onset atrial fibrillation (AF) in patients with hypertension, or for the secondary prevention in patients with recurrent AF receiving antiarrhythmic drug therapy. </p><p>The 2014 American Heart <span class=\"nowrap\">Association/American</span> College of <span class=\"nowrap\">Cardiology/Heart</span> Rhythm Society AF guideline makes a weak recommendation for the use of angiotensin inhibition for the primary prevention of new-onset AF in patients with HF with reduced left ventricular ejection fraction [<a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/39,40\" class=\"abstract_t\">39,40</a>].</p><p>The 2010 ESC guidelines for the management of AF made the following recommendations for the use of angiotensin inhibition:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For primary prevention of AF:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Weak recommendations were made for the prevention new onset AF in patients with heart failure and a reduced ejection fraction as well as for those with hypertension, particularly with left ventricular hypertrophy.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Upstream angiotensin inhibition was not recommended for the prevention of AF in patients without cardiovascular disease; no recommendation was made for those with cardiovascular disease.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For secondary prevention of AF, pretreatment with angiotensin inhibition may be considered in patients with recurrent AF and receiving antiarrhythmic drug therapy.</p><p/><p class=\"headingAnchor\" id=\"H2908013410\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-atrial-fibrillation\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Atrial fibrillation&quot;</a> and <a href=\"topic.htm?path=society-guideline-links-arrhythmias-in-adults\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Arrhythmias in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with a cardiovascular condition, such as heart failure or hypertension, in which the use of an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) might be either indicated or reasonable, it is possible that their use might reduce the likelihood of new or recurrent atrial fibrillation (AF). However, we do not recommend angiotensin inhibition in preference to other therapy solely for the prevention of AF. (See <a href=\"#H9\" class=\"local\">'Prevention of recurrent AF'</a> above.) </p><p>There is a plausible scientific basis for the notion that inhibition of the renin-angiotensin-aldosterone system can reduce the incidence of AF. Possible mechanisms include reducing atrial stretch, limiting atrial fibrosis, inhibiting triggering from the pulmonary veins, and preventing atrial remodeling. (See <a href=\"#H2\" class=\"local\">'Possible mechanisms'</a> above.)</p><p>Secondary analyses of randomized trials performed for reasons other than AF prevention suggest that ACE inhibitors and ARBs reduce the incidence of new onset AF. However, publication bias and heterogeneity of the trials renders the evidence to support their use weak. The greatest benefit was seen in patients with heart <span class=\"nowrap\">failure/left</span> ventricular dysfunction in whom therapy with an ACE inhibitor or ARB is probably already indicated. (See <a href=\"#H3\" class=\"local\">'Prevention of new onset AF'</a> above.)</p><p>Our recommendations for the use of angiotensin blockade to prevent AF are as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients at risk for AF but without an indication for angiotensin blockade, we recommend NOT initiating therapy with an ACE inhibitor or ARB solely to prevent new onset AF (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). &#160; </p><p/><p class=\"bulletIndent1\">For patients with a history of both AF and hypertension requiring medical treatment, it is reasonable to use an ACE inhibitor or ARB (or change other antihypertensive medical therapy to an ACE inhibitor or ARB) given the possibility that this may reduce the risk of recurrent AF in addition to treatment of hypertension.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with a history of AF, we recommend NOT treating with an ACE inhibitor or ARB for the sole purpose of preventing recurrent AF (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). (See <a href=\"#H9\" class=\"local\">'Prevention of recurrent AF'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We do not recommend use of an angiotensin receptor blocker for the prevention of cardiovascular events in patients with AF whose blood pressure is at or below goal. (See <a href=\"#H110572908\" class=\"local\">'Prevention of cardiovascular events'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/1\" class=\"nounderline abstract_t\">Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006; 27:512.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/2\" class=\"nounderline abstract_t\">Webster MW, Fitzpatrick MA, Nicholls MG, et al. Effect of enalapril on ventricular arrhythmias in congestive heart failure. Am J Cardiol 1985; 56:566.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/3\" class=\"nounderline abstract_t\">McEwan PE, Gray GA, Sherry L, et al. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 1998; 98:2765.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/4\" class=\"nounderline abstract_t\">Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104:2608.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/5\" class=\"nounderline abstract_t\">Sakabe M, Fujiki A, Nishida K, et al. Enalapril prevents perpetuation of atrial fibrillation by suppressing atrial fibrosis and over-expression of connexin43 in a canine model of atrial pacing-induced left ventricular dysfunction. J Cardiovasc Pharmacol 2004; 43:851.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/6\" class=\"nounderline abstract_t\">Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101:2612.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/7\" class=\"nounderline abstract_t\">Sicouri S, Cordeiro JM, Talarico M, Antzelevitch C. Antiarrhythmic effects of losartan and enalapril in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol 2011; 22:698.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/8\" class=\"nounderline abstract_t\">Zhang Y, Zhang P, Mu Y, et al. The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Clin Pharmacol Ther 2010; 88:521.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/9\" class=\"nounderline abstract_t\">Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100:376.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/10\" class=\"nounderline abstract_t\">Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107:2926.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/11\" class=\"nounderline abstract_t\">Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149:548.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/12\" class=\"nounderline abstract_t\">Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152:86.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/13\" class=\"nounderline abstract_t\">Schaer BA, Schneider C, Jick SS, et al. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med 2010; 152:78.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/14\" class=\"nounderline abstract_t\">L'Allier PL, Ducharme A, Keller PF, et al. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004; 44:159.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/15\" class=\"nounderline abstract_t\">Dahl&ouml;f B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/16\" class=\"nounderline abstract_t\">Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45:712.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/17\" class=\"nounderline abstract_t\">Heckbert SR, Wiggins KL, Glazer NL, et al. Antihypertensive treatment with ACE inhibitors or beta-blockers and risk of incident atrial fibrillation in a general hypertensive population. Am J Hypertens 2009; 22:538.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/18\" class=\"nounderline abstract_t\">Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/19\" class=\"nounderline abstract_t\">Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/20\" class=\"nounderline abstract_t\">Yamashita T, Inoue H, Okumura K, et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace 2011; 13:473.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/21\" class=\"nounderline abstract_t\">Schneider MP, Hua TA, B&ouml;hm M, et al. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010; 55:2299.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/22\" class=\"nounderline abstract_t\">Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106:331.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/23\" class=\"nounderline abstract_t\">Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003; 24:2090.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/24\" class=\"nounderline abstract_t\">Yin Y, Dalal D, Liu Z, et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 2006; 27:1841.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/25\" class=\"nounderline abstract_t\">Fogari R, Mugellini A, Destro M, et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol 2006; 47:46.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/26\" class=\"nounderline abstract_t\">Belluzzi F, Sernesi L, Preti P, et al. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 2009; 53:24.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/27\" class=\"nounderline abstract_t\">Galzerano D, Di Michele S, Paolisso G, et al. A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients. J Renin Angiotensin Aldosterone Syst 2012; 13:496.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/28\" class=\"nounderline abstract_t\">GISSI-AF Investigators, Disertori M, Latini R, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360:1606.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/29\" class=\"nounderline abstract_t\">Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45:1832.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/30\" class=\"nounderline abstract_t\">Goette A, Sch&ouml;n N, Kirchhof P, et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol 2012; 5:43.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/31\" class=\"nounderline abstract_t\">Zhao J, Li J, Li W, et al. Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing. Br J Pharmacol 2010; 159:1584.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/32\" class=\"nounderline abstract_t\">Dabrowski R, Borowiec A, Smolis-Bak E, et al. Effect of combined spironolactone-&beta;-blocker &plusmn; enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study). Am J Cardiol 2010; 106:1609.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/33\" class=\"nounderline abstract_t\">Swedberg K, Zannad F, McMurray JJ, et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 2012; 59:1598.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/34\" class=\"nounderline abstract_t\">Ito Y, Yamasaki H, Naruse Y, et al. Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation. Am J Cardiol 2013; 111:1012.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/35\" class=\"nounderline abstract_t\">Klemm HU, Heitzer T, Ruprecht U, et al. Impact of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the long-term outcome after pulmonary vein isolation for paroxysmal atrial fibrillation. Cardiology 2010; 117:14.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/36\" class=\"nounderline abstract_t\">Richter B, Derntl M, Marx M, et al. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation. Am Heart J 2007; 153:113.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/37\" class=\"nounderline abstract_t\">Al Chekakie MO, Akar JG, Wang F, et al. The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation. J Cardiovasc Electrophysiol 2007; 18:942.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/38\" class=\"nounderline abstract_t\">ACTIVE I Investigators, Yusuf S, Healey JS, et al. Irbesartan in patients with atrial fibrillation. N Engl J Med 2011; 364:928.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/39\" class=\"nounderline abstract_t\">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:2071.</a></li><li><a href=\"https://www.uptodate.com/contents/ace-inhibitors-angiotensin-receptor-blockers-and-atrial-fibrillation/abstract/40\" class=\"nounderline abstract_t\">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:e199.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 935 Version 17.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H11\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">POSSIBLE MECHANISMS</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">PREVENTION OF NEW ONSET AF</a><ul><li><a href=\"#H6\" id=\"outline-link-H6\">Left ventricular dysfunction or heart failure</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Hypertension</a></li><li><a href=\"#H621977831\" id=\"outline-link-H621977831\">Patients with other risk factors for AF</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Coronary artery bypass graft</a></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">PREVENTION OF RECURRENT AF</a><ul><li><a href=\"#H615512240\" id=\"outline-link-H615512240\">Aldosterone inhibition and AF</a></li><li><a href=\"#H615512079\" id=\"outline-link-H615512079\">Catheter ablation of AF</a></li></ul></li><li><a href=\"#H110572908\" id=\"outline-link-H110572908\">PREVENTION OF CARDIOVASCULAR EVENTS</a></li><li><a href=\"#H986438\" id=\"outline-link-H986438\">RECOMMENDATIONS OF OTHERS</a></li><li><a href=\"#H2908013410\" id=\"outline-link-H2908013410\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=actions-of-angiotensin-ii-on-the-heart\" class=\"medical medical_review\">Actions of angiotensin II on the heart</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=angiotensin-converting-enzyme-inhibitors-and-receptor-blockers-in-acute-myocardial-infarction-clinical-trials\" class=\"medical medical_review\">Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=atrial-fibrillation-and-flutter-after-cardiac-surgery\" class=\"medical medical_review\">Atrial fibrillation and flutter after cardiac surgery</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=atrial-fibrillation-anticoagulant-therapy-to-prevent-embolization\" class=\"medical medical_review\">Atrial fibrillation: Anticoagulant therapy to prevent embolization</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=catheter-ablation-to-prevent-recurrent-atrial-fibrillation-clinical-applications\" class=\"medical medical_review\">Catheter ablation to prevent recurrent atrial fibrillation: Clinical applications</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=choice-of-drug-therapy-in-primary-essential-hypertension\" class=\"medical medical_review\">Choice of drug therapy in primary (essential) hypertension</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-of-and-risk-factors-for-atrial-fibrillation\" class=\"medical medical_review\">Epidemiology of and risk factors for atrial fibrillation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-arrhythmias-in-adults\" class=\"medical medical_society_guidelines\">Society guideline links: Arrhythmias in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-atrial-fibrillation\" class=\"medical medical_society_guidelines\">Society guideline links: Atrial fibrillation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=the-electrocardiogram-in-atrial-fibrillation\" class=\"medical medical_review\">The electrocardiogram in atrial fibrillation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=use-of-angiotensin-converting-enzyme-inhibitors-in-heart-failure-with-reduced-ejection-fraction\" class=\"medical medical_review\">Use of angiotensin converting enzyme inhibitors in heart failure with reduced ejection fraction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=use-of-mineralocorticoid-receptor-antagonists-in-heart-failure-with-reduced-ejection-fraction\" class=\"medical medical_review\">Use of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=what-is-goal-blood-pressure-in-the-treatment-of-hypertension\" class=\"medical medical_review\">What is goal blood pressure in the treatment of hypertension?</a></li></ul></div></div>","javascript":null}